Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CG Oncology, Inc. (CGON)

CG Oncology's Q2 net loss widens to $79.1 million; adds $500 million stock sale capacity

Negative Impact 4 of 5 financing Written later

CG Oncology reported a second-quarter 2026 net loss of $79.1 million, or $(0.90) per share, up from $41.4 million, or $(0.54), a year earlier, on revenue of $1.2 million. The company also filed an amendment to increase by $500.0 million the shares it can sell under its Jefferies at-the-market sale agreement, which could add to dilution for existing shareholders.

Key points

  • Q2 2026 net loss was $79.1 million, or $(0.90) per share, versus $41.4 million, or $(0.54) per share, in Q2 2025.
  • Research and development expenses were $54.7 million, compared with $31.3 million a year earlier.
  • Cash, cash equivalents and marketable securities were $1.0 billion as of June 30, 2026, down from $1.1 billion as of March 31, 2026.
  • Amendment No. 2 adds $500.0 million of shares available under the Jefferies sale agreement dated March 28, 2025, after about $550.0 million was previously sold.

The filing

CompanyCG Oncology, Inc. (CGON)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:30 AM ET
Accession number0001193125-26-336886

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.